Explore how pharmaceutical companies extend market dominance beyond patent expiration using regulatory exclusivities, PTEs, and evergreening strategies in the US and EU.
More
Paragraph IV patent challenges let generic drug makers legally fight brand patents to bring cheaper drugs to market. Under the Hatch-Waxman Act, the first challenger gets 180 days of exclusivity-making it a high-stakes game of law, money, and patient access.
More